A 2016 Danish study showed remnant cholesterol, VLDL, was as critical as LDL cholesterol in myocardial infarction and ischemic stroke. Is it a practice impact opportunity that deserves closer attention to reduce the incidence of myocardial infarction and stroke?

Impressive results from the trial on PCKS9 inhibitors include a 59% reduction in LDL cholesterol and 25% reduction in CV death, MI, and stroke, with new findings on safety. Is the high cost sustainable, and what will the longer, ongoing ODYSSEY trial show?

For cardiologists considering treatment options for chronic stable angina with moderate to severe myocardial ischemia, the ISCHEMIA Trial offers evidence on the benefit of optimal medical management and treatment versus invasive therapy.

If the five-year data on the Scott Hart reported in 2018 showed that the use of CTA in addition to standard care resulted in more correct diagnosis of coronary artery disease than standard care alone, then is it time we lowered the threshold for referring patients for CTA?

The COLCOT Trial’s 4,700 patients were randomized to 0.5mg of Colchicine per day for 22 months. Trial outcomes saw impressive reductions in CV events, but is the anti-inflammatory a game-changer?

CANTOS finds the drug Canakinumab’s impact on cholesterol levels, inflammation, and coronary artery events range from none to significant, and delivers important analysis from its pre-specified cancer event look.

Dr. Bernie discusses the treatment of cholesterol in patients who have had a heart attack or acute coronary syndrome.

The RECOVERY trial yields a promising intervention option to watchful waiting for asymptomatic patients with very severe aortic stenosis.

Dr. Bernie sees the DAPA2 trial as a game-changer in the treatment of heart failure, but what’s the greatest benefit of its impact on the elderly?

Dr. Bernie explains how the EVAPORATE trial sheds light on the CV benefits of the REDUCE-IT trial and what it means for US population outcomes.